Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Bernstein Clinical Research Center
Study ID
NCT06818474
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Angioedema

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lanadelumab 300 mg — BIOLOGICAL
    no other intervention

Study Details

use of lanadelumab in patients with acquired angioedema

Key Dates

Start date
Jun 1, 2024
Status verified
Feb 2025
Primary completion
Sep 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: open-label administration
    all subjects receive open-label lanadelumab

Primary Outcome Measure

Primary Objective [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Bernstein Clinical Research Center, LLCCincinnatiOhio45236
Karen Berendts
[email protected]
513-354-1746
Jonathan Bernstein, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cincinnati, OH

By research site
Bernstein Clinical Research Center, LLC· Cincinnati, OH

Related Studies